Gema L Ramírez-Salinas, Tolentino-Lopez L E, Martínez-Ramos F, Padilla-Martínez I, García-Machorro J, Correa-Basurto J
Laboratorio de Modelado Molecular y Diseño de Fármacos (Laboratory of Molecular Modeling and Drug Design), Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México City, Mexico.
J Mol Model. 2015 Jan;21(1):8. doi: 10.1007/s00894-014-2525-9. Epub 2015 Jan 22.
Following the influenza A (H1N1) pandemic in Mexico and around the world in 2009, the numbers of oseltamivir-resistant clinical cases have increased through a mechanism that remains unclear. In this work, we focus on studying the mutated NA structures ADA71175 (GenBank) and 3CKZ (PDB ID). Recently crystallized NA (PDB ID: 3NSS) was used as a wild-type structure and template to construct the three-dimensional (3D) structure of ADA71175. Then, the NA mutants and 3NSS natives as well as their refined monomer structures as determined through MD simulations (snapshots at 50 ns) were used as models to perform a docking study using a set of aryl-oseltamivir derivatives. These aryl-oseltamivir derivatives have better recognition properties than oseltamivir because of cation-π interactions with a cluster of Arg residues (118, 292, and 371) at the binding site. This cluster of Arg residues represents a potential binding site for aryl-oseltamivir derivatives that are potentially new NA inhibitors.
2009年墨西哥及全球爆发甲型H1N1流感大流行后,对奥司他韦耐药的临床病例数量通过一种尚不清楚的机制有所增加。在这项研究中,我们着重研究突变的神经氨酸酶(NA)结构ADA71175(基因库)和3CKZ(蛋白质数据银行ID)。最近结晶的NA(蛋白质数据银行ID:3NSS)被用作野生型结构和模板来构建ADA71175的三维(3D)结构。然后,将通过分子动力学模拟确定的NA突变体和3NSS天然型及其优化的单体结构(50纳秒时的快照)用作模型,使用一组芳基奥司他韦衍生物进行对接研究。这些芳基奥司他韦衍生物由于与结合位点处的一组精氨酸残基(118、292和371)存在阳离子-π相互作用,因而具有比奥司他韦更好的识别特性。这组精氨酸残基代表了芳基奥司他韦衍生物的一个潜在结合位点,这些衍生物可能是新型的NA抑制剂。